Breaking News

Alvogen Appoints Americas Head

October 31, 2013

Alkins brings 25 years of commercial experience

Darren Alkins has been appointed president of Alvogen Americas and will become a member of the executive board. Mr. Alkins will be leading Alvogen’s sales, marketing and business development efforts in North and South America. He will also be responsible for Alvogen’s third party business units in the U.S., including Norwich Pharma Services, a contract manufacturing and clinical research organization based in Norwich, NY.
Mr. Alkins brings 25 years of commercial experience in brand and generic sales and marketing, as well as third party business development. Most recently, he led the business development and alliance management team for Teva Pharmaceuticals, driving key initiatives developing new and existing business for the company in the U.S. He also served as senior vice president of corporate development at Stiefel Laboratories and president of Glades Pharmaceuticals. He began his career at Bristol-Myers Squibb, and was promoted through various sales, marketing, operations and business development functions.
“I am delighted to welcome Darren to the executive board, a role for which he is well prepared through his extensive industry experience. With more than 25 years of commercial experience in both branded and generic pharmaceuticals, Darren’s successful history driving key organizational initiatives, expertise and leadership will help lead Alvogen into our next phase of growth,” said Robert Wessman, chairman and chief executive officer of Alvogen.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks